Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company, which engages in the provision of medical solutions for unmet immunological, urological, neurological, and orthopedic needs. It develops intellectual property portfolio utilizing stem cells and interrelated technologies for the treatment of erectile dysfunction and female sexual dysfunction. The company was founded on December 3, 1998 and is headquartered in Phoenix, AZ.
相关临床试验
4
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1998
进行中（未招募）
1
25.0%
Available
1
25.0%
尚未招募
1
25.0%
招募中
1
25.0%
暂无批准数据
- Creative Medical Technology Holdings (CELZ) announced the nationwide virtual launch of Project PHOENIX, a regulatory-approved AI-driven registry for U.S. veterans exposed to burn pits and toxic hazards. - The decentralized platform uses a mobile app and field-capable logistics to enroll at least 1,000 veterans, capturing exposure history, symptoms, and longitudinal health data without requiring travel to centralized sites. - Multi-omics profiling combined with AI interpretation will compare exposed veterans against non-exposed populations to identify biomarkers, disease pathways, and therapeutic targets for drugs, biologics, and regenerative therapies. - The company is developing the CELZ-Biodefense Toxic Exposure Atlas, a proprietary discovery asset intended to accelerate therapeutic development and position CELZ as a next-generation Regenerative BioDefense company.
- Ultrasome™, a cell-free regenerative therapy derived from CELZ-201, achieved a 93% response rate in a knee osteoarthritis pilot study with no serious adverse events reported. - The therapy leverages GMP-produced CELZ-201 (Olastrocel) biological signaling components in a cell-free format, enabling scalable manufacturing and off-the-shelf availability. - Osteoarthritis affects over 30 million adults in the United States, representing a multi-billion-dollar market with limited treatment options beyond symptom management and invasive procedures. - Creative Medical plans to expand clinical execution, generate additional data, and evaluate strategic pathways toward commercialization and partnerships.
- Creative Medical Technology's StemSpine pilot study demonstrates significant long-term success, with over 90% of chronic back pain patients eliminating opioid use three years post-treatment. - The study reports an 80% sustained reduction in pain scores and more than 60% improvement in functional mobility as measured by the Oswestry Disability Index. - Treatment using AlloStem cells shows strong safety profile with no serious adverse events and only one patient requiring reintervention after three years.
- Initial data from the first cohort of 10 participants demonstrates excellent safety profile for CELZ-201-DDT stem cell therapy, with no serious adverse events reported in degenerative disc disease treatment. - Blinded preliminary results indicate potential therapeutic benefits in alleviating chronic back pain and improving functionality, marking a significant step in stem cell-based treatments. - Independent Data Safety Monitoring Board has approved progression to the second cohort, with enrollment expected to begin in Q1 2025.
